Selected research
Industry Growth & Trends
Global Female Infertility Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Female Infertility Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Female Infertility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Female Infertility Drugs market include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Female Infertility Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Female Infertility Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Female Infertility Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Female Infertility Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Female Infertility Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Female Infertility Drugs Market by Company
Allergan Plc
Ferring BV
Merck KGaA
Novartis AG
Sanofi
Female Infertility Drugs Segment by Type
Parenteral
Oral
Others
Female Infertility Drugs Segment by Application
Low Birth Weight
Multiple-gestation Pregnancies
Multiple-birth Infants
Ovarian Hyperstimulation Syndrome
Risk of Cesarean Delivery
Premature Labor
Female Infertility Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Infertility Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Female Infertility Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Infertility Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Female Infertility Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Parenteral
- Oral
- Others
Applications
- Low Birth Weight
- Multiple-gestation Pregnancies
- Multiple-birth Infants
- Ovarian Hyperstimulation Syndrome
- Risk of Cesarean Delivery
- Premature Labor
Companies covered
- Allergan Plc
- Ferring BV
- Merck KGaA
- Novartis AG
- Sanofi
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Female Infertility Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Female Infertility Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Female Infertility Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Female Infertility Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Female Infertility Drugs Market Size (2021-2032)
- 1.5.1 North America Female Infertility Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Female Infertility Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Female Infertility Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Female Infertility Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Female Infertility Drugs Market Size Growth Rate (2021-2032)
2 Female Infertility Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Parenteral
- 2.1.2 Oral
- 2.1.3 Others
- 2.2 Global Female Infertility Drugs Market Size by Type
- 2.2.1 Global Female Infertility Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Female Infertility Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Female Infertility Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Female Infertility Drugs Market Size by Regions
- 2.3.1 North America Female Infertility Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Female Infertility Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Female Infertility Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Female Infertility Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Female Infertility Drugs Market Size Breakdown by Type (2021-2026)
3 Female Infertility Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Low Birth Weight
- 3.1.2 Multiple-gestation Pregnancies
- 3.1.3 Multiple-birth Infants
- 3.1.4 Ovarian Hyperstimulation Syndrome
- 3.1.5 Risk of Cesarean Delivery
- 3.1.6 Premature Labor
- 3.2 Global Female Infertility Drugs Market Size by Application
- 3.2.1 Global Female Infertility Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Female Infertility Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Female Infertility Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Female Infertility Drugs Market Size by Regions
- 3.3.1 North America Female Infertility Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Female Infertility Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Female Infertility Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Female Infertility Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Female Infertility Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Female Infertility Drugs Industry Trends
- 4.2 Female Infertility Drugs Industry Drivers
- 4.3 Female Infertility Drugs Industry Opportunities and Challenges
- 4.4 Female Infertility Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Female Infertility Drugs Revenue (2021-2026)
- 5.2 Global Female Infertility Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Female Infertility Drugs Key Company Headquarters & Area Served
- 5.4 Global Female Infertility Drugs Company, Product Type & Application
- 5.5 Global Female Infertility Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Female Infertility Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Female Infertility Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Female Infertility Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Allergan Plc
- 6.1.1 Allergan Plc Company Information
- 6.1.2 Allergan Plc Business Overview
- 6.1.3 Allergan Plc Female Infertility Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Allergan Plc Female Infertility Drugs Product Portfolio
- 6.1.5 Allergan Plc Recent Developments
- 6.2 Ferring BV
- 6.2.1 Ferring BV Company Information
- 6.2.2 Ferring BV Business Overview
- 6.2.3 Ferring BV Female Infertility Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Ferring BV Female Infertility Drugs Product Portfolio
- 6.2.5 Ferring BV Recent Developments
- 6.3 Merck KGaA
- 6.3.1 Merck KGaA Company Information
- 6.3.2 Merck KGaA Business Overview
- 6.3.3 Merck KGaA Female Infertility Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck KGaA Female Infertility Drugs Product Portfolio
- 6.3.5 Merck KGaA Recent Developments
- 6.4 Novartis AG
- 6.4.1 Novartis AG Company Information
- 6.4.2 Novartis AG Business Overview
- 6.4.3 Novartis AG Female Infertility Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novartis AG Female Infertility Drugs Product Portfolio
- 6.4.5 Novartis AG Recent Developments
- 6.5 Sanofi
- 6.5.1 Sanofi Company Information
- 6.5.2 Sanofi Business Overview
- 6.5.3 Sanofi Female Infertility Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sanofi Female Infertility Drugs Product Portfolio
- 6.5.5 Sanofi Recent Developments
7 North America
- 7.1 North America Female Infertility Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Female Infertility Drugs Market Size by Country (2021-2026)
- 7.3 North America Female Infertility Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Female Infertility Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Female Infertility Drugs Market Size by Country (2021-2026)
- 8.3 Europe Female Infertility Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Female Infertility Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Female Infertility Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Female Infertility Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Female Infertility Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Female Infertility Drugs Market Size by Country (2021-2026)
- 10.3 South America Female Infertility Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Female Infertility Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Female Infertility Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Female Infertility Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst